{"id":130453,"date":"2026-06-25T11:04:07","date_gmt":"2026-06-25T05:34:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=130453"},"modified":"2026-06-25T11:04:09","modified_gmt":"2026-06-25T05:34:09","slug":"aurobindo-pharma-q1-results-fy27","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/","title":{"rendered":"Aurobindo Pharma Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Aurobindo Pharma Q1 Results FY27: Uniresearch projects Revenue Rs 9,064 Cr | PAT Rs 1,064 Cr (28-analyst consensus). Q4 FY26: Rev Rs 8,853 Cr | PAT Rs 921 Cr.<\/em><\/p>\n<p>The <a href=\"https:\/\/univest.in\/stocks\/auropharm\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a> Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 28-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 9,064 Cr (+15.2% YoY) and PAT Rs 1,064 Cr (+29.1% YoY). Prepared by Kunal Singla.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aurobindo-pharma-q1-results-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Aurobindo_Pharma_Q1_Results_FY27_%E2%80%93_Uniresearch_Prediction\" title=\"Aurobindo Pharma Q1 Results FY27 &#8211; Uniresearch Prediction\">Aurobindo Pharma Q1 Results FY27 &#8211; Uniresearch Prediction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Aurobindo_Pharma_Q4_FY26_Key_Metrics\" title=\"Aurobindo Pharma Q4 FY26 Key Metrics\">Aurobindo Pharma Q4 FY26 Key Metrics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_Analysts_Are_Saying_About_Aurobindo_Pharma\" title=\"What Analysts Are Saying About Aurobindo Pharma\">What Analysts Are Saying About Aurobindo Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Key_Watchpoints_for_Aurobindo_Pharma\" title=\"Key Watchpoints for Aurobindo Pharma\">Key Watchpoints for Aurobindo Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Revenue_Delivery_vs_Consensus\" title=\"Revenue Delivery vs Consensus\">Revenue Delivery vs Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#PAT_Delivery_in_Q1_FY27\" title=\"PAT Delivery in Q1 FY27\">PAT Delivery in Q1 FY27<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Risks_to_the_Aurobindo_Pharma_Prediction\" title=\"Risks to the Aurobindo Pharma Prediction\">Risks to the Aurobindo Pharma Prediction<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Revenue_Miss_vs_Consensus\" title=\"Revenue Miss vs Consensus\">Revenue Miss vs Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#PAT_Pressure\" title=\"PAT Pressure\">PAT Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Conclusion_Aurobindo_Pharma\" title=\"Conclusion: Aurobindo Pharma\">Conclusion: Aurobindo Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#Frequently_Asked_Questions_on_Aurobindo_Pharma\" title=\"Frequently Asked Questions on Aurobindo Pharma\">Frequently Asked Questions on Aurobindo Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_is_Uniresearchs_PAT_prediction_for_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What is Uniresearch&#8217;s PAT prediction for Aurobindo Pharma Q1 Results FY27?\">What is Uniresearch&#8217;s PAT prediction for Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_is_the_Revenue_prediction_for_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What is the Revenue prediction for Aurobindo Pharma Q1 Results FY27?\">What is the Revenue prediction for Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_were_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What were Aurobindo Pharma Q1 Results FY27?\">What were Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#How_many_analysts_back_the_Aurobindo_Pharma_Q1_Results_FY27\" title=\"How many analysts back the Aurobindo Pharma Q1 Results FY27?\">How many analysts back the Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_FY27_growth_consensus_was_applied_for_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What FY27 growth consensus was applied for Aurobindo Pharma Q1 Results FY27?\">What FY27 growth consensus was applied for Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_are_the_key_risks_to_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What are the key risks to Aurobindo Pharma Q1 Results FY27?\">What are the key risks to Aurobindo Pharma Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-q1-results-fy27\/#What_is_the_Q1_FY26_base_for_Aurobindo_Pharma_Q1_Results_FY27\" title=\"What is the Q1 FY26 base for Aurobindo Pharma Q1 Results FY27?\">What is the Q1 FY26 base for Aurobindo Pharma Q1 Results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Q1_Results_FY27_%E2%80%93_Uniresearch_Prediction\"><\/span><strong>Aurobindo Pharma Q1 Results FY27 &#8211; Uniresearch Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 16px 0;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Metric<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q1 FY26 Actual<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q1 FY27 Uniresearch Prediction<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>YoY Change<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Source<\/strong><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\"><a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a> Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">7,868<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">9,064<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+15.2%<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Uniresearch | 28-analyst consensus applied to Q1 FY26 verified actual<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">824<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">1,064<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+29.1%<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Uniresearch | 28-analyst consensus applied to Q1 FY26 verified actual<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Avg Analyst Target<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Rs 1,517<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">12-month view<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">&#8211;<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Analyst consensus (28 analysts)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-size: 12px; color: #666;\"><em>Predictions apply 28-analyst FY27 consensus (Rev +15.2%, PAT +29.1%) to Q1 FY26 verified actuals. Not guaranteed outcomes.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Q4_FY26_Key_Metrics\"><\/span><strong>Aurobindo Pharma Q4 FY26 Key Metrics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 16px 0;\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Metric<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Q4 FY26 Actual<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>YoY Change<\/strong><\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; background: #EBF3FB;\"><strong>Source<\/strong><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">8,853<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+5.6% YoY<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Consolidated quarterly financial data<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">921<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">+2.0% YoY<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Consolidated quarterly financial data<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Are_Saying_About_Aurobindo_Pharma\"><\/span><strong>What Analysts Are Saying About Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Across 28 analysts covering Aurobindo Pharma, the FY27 consensus projects revenue growth of +15.2% and profit growth of +29.1%, with an average 12-month price target of Rs 1,517.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Watchpoints_for_Aurobindo_Pharma\"><\/span><strong>Key Watchpoints for Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Delivery_vs_Consensus\"><\/span><strong>Revenue Delivery vs Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether Aurobindo Pharma delivers Revenue Rs 9,064 Cr (+15.2% consensus growth) is the primary watchpoint. Q1 FY26 base was Rs 7,868 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Delivery_in_Q1_FY27\"><\/span><strong>PAT Delivery in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT is projected at Rs 1,064 Cr (+29.1% vs Q1 FY26 base of Rs 824 Cr). Q4 FY26 PAT was Rs 921 Cr.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_the_Aurobindo_Pharma_Prediction\"><\/span><strong>Risks to the Aurobindo Pharma Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Miss_vs_Consensus\"><\/span><strong>Revenue Miss vs Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue falling below the +15.2% consensus would result in actual revenue below Rs 9,064 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Pressure\"><\/span><strong>PAT Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Unexpected margin or cost factors could affect PAT delivery against the +29.1% growth consensus.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Aurobindo_Pharma\"><\/span><strong>Conclusion: Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aurobindo Pharma Uniresearch prediction of Revenue Rs 9,064 Cr and PAT Rs 1,064 Cr is derived from the 28-analyst FY27 consensus applied to verified Q1 FY26 actuals. Track live updates on Univest.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Aurobindo Pharma Live on the Univest Screener<\/strong><\/a><\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Q1 FY27 alerts.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals. These are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Aurobindo_Pharma\"><\/span><strong>Frequently Asked Questions on Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Uniresearchs_PAT_prediction_for_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What is Uniresearch&#8217;s PAT prediction for Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Uniresearch projects Aurobindo Pharma Q1 FY27 PAT at Rs 1,064 Cr (+29.1% consensus), based on Q1 FY26 actual PAT of Rs 824 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Revenue_prediction_for_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What is the Revenue prediction for Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma Q1 Revenue is projected at Rs 9,064 Cr, applying +15.2% FY27 revenue consensus to Q1 FY26 base of Rs 7,868 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What were Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q4 FY26 consolidated Revenue was Rs 8,853 Cr (+5.6% YoY) and PAT was Rs 921 Cr (+2.0% YoY).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_many_analysts_back_the_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>How many analysts back the Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Aurobindo Pharma Q1 prediction uses the 28-analyst FY27 consensus with an average 12-month target of Rs 1,517.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_FY27_growth_consensus_was_applied_for_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What FY27 growth consensus was applied for Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue growth of +15.2% and profit growth of +29.1% (28-analyst consensus).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What are the key risks to Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Risks include revenue missing the +15.2% consensus target and PAT pressure beyond the +29.1% consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Q1_FY26_base_for_Aurobindo_Pharma_Q1_Results_FY27\"><\/span><strong>What is the Q1 FY26 base for Aurobindo Pharma Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q1 FY26 consolidated Revenue Rs 7,868 Cr and PAT Rs 824 Cr.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue Rs 9,064 Cr and PAT Rs 1,064 Cr (28-analyst consensus). Q4 FY26 actuals, analyst views and watchpoints inside.<\/p>\n","protected":false},"author":28,"featured_media":130609,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,4734],"class_list":["post-130453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q1-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782365651:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Aurobindo Pharma Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints"],"rank_math_description":["Aurobindo Pharma Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue Rs 9,064 Cr and PAT Rs 1,064 Cr (28-analyst consensus). Q4 FY26 actuals, analyst views and watchpoints inside."],"rank_math_focus_keyword":["Aurobindo Pharma Q1 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["130609"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21110"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Aurobindo-Pharma-Q1-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=130453"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130453\/revisions"}],"predecessor-version":[{"id":130612,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/130453\/revisions\/130612"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/130609"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=130453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=130453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=130453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}